{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:23:12Z","timestamp":1793330592130,"version":"4.5.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background and aims<\/jats:title>\n<jats:p>Autoimmune hemolytic anemia (AIHA) and cold agglutinin disease (CAD) are debilitating conditions characterized by chronic hemolysis and severe anemia. The existing epidemiological estimates in the United States (US) remain limited because of the rarity of AIHA and CAD. This retrospective study aims to update the epidemiology of AIHA and CAD in the US from 2016 to 2023 by separately analyzing administrative claims data from Optum\u2019s de-identified Clinformatics<jats:sup>\u00ae<\/jats:sup> Data Mart (Optum CDM), Inovalon\u2019s Medical Outcomes Research for Effectiveness and Economics (MORE<jats:sup>2<\/jats:sup>) Registry, and Medicare Fee for Service (FFS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study consisted of patients aged \u226518 years with 180 days of continuous enrollment in their health plan. The index date was the first observed claim with AIHA or CAD ICD-9\/10 diagnosis codes. The 2016\u20132021 US Census data were used to standardize incidence and prevalence estimates by age and sex. The results were presented by the US states.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The AIHA incidence ranged from 1.4 to 6.6 per 100,000 persons across the databases. The CAD incidence ranged from 0.6 to 1.2 per 100,000 persons across the databases, with Medicare FFS estimates being the highest. Prevalence estimates also varied, with the AIHA 1-year prevalence ranging from 4.2 to 20.6 per 100,000 persons and CAD from 1.4 to 3.1 per 100,000 persons across the databases.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This multi-database analysis provides the updated epidemiological estimates of AIHA and CAD in the US, showing a higher incidence and prevalence in females than males, with both conditions increasing with age. However, no clear geographic pattern emerged across the US.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323843","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:48:18Z","timestamp":1750960098000},"page":"e0323843","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016\u20132023"],"prefix":"10.1371","volume":"20","author":[{"given":"Sylvie","family":"Bozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhi","family":"Umarje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-4081","authenticated-orcid":true,"given":"Kalyani","family":"Hawaldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tyma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabie","family":"Agatep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-1562","authenticated-orcid":true,"given":"Zulkarnain","family":"Pulungan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5133-1516","authenticated-orcid":true,"given":"Natalia","family":"Petruski-Ivleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"pone.0323843.ref001","author":"DelveInsight","year":"2020"},{"key":"pone.0323843.ref002","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/CLEP.S250250","article-title":"Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980-2016","volume":"12","author":"DL Hansen","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"20","key":"pone.0323843.ref003","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/bloodadvances.2019000476","article-title":"Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease","volume":"3","author":"LC Bylsma","year":"2019","journal-title":"Blood Adv"},{"key":"pone.0323843.ref004","author":"Hematology, ASH\u00ae Education Program","year":"2018"},{"key":"pone.0323843.ref005","author":"National Organization for Rare Disorders (NORD)"},{"issue":"10","key":"pone.0323843.ref006","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"A Zanella","year":"2014","journal-title":"Haematologica"},{"key":"pone.0323843.ref007","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The Changing Landscape of Autoimmune Hemolytic Anemia","volume":"11","author":"W Barcellini","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0323843.ref008","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"S Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"pone.0323843.ref009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"SS Michalak","year":"2020","journal-title":"Immun Ageing"},{"key":"pone.0323843.ref010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/JBM.S177621","article-title":"Cold agglutinin disease: current challenges and future prospects","volume":"10","author":"S Berentsen","year":"2019","journal-title":"J Blood Med"},{"issue":"6281","key":"pone.0323843.ref011","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/bmj.282.6281.2023","article-title":"Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre","volume":"282","author":"RJ Sokol","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"4","key":"pone.0323843.ref012","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"S Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"pone.0323843.ref013","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis","volume":"4","author":"CM Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"pone.0323843.ref014","doi-asserted-by":"crossref","first-page":"456","DOI":"10.29271\/jcpsp.2018.06.456","article-title":"Relation between Depressive Disorder and Iron Deficiency Anemia among Adults Reporting to a Secondary Healthcare Facility: A Hospital-Based Case Control Study","volume":"28","author":"M Shafi","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"issue":"2","key":"pone.0323843.ref015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/acps.12595","article-title":"Association between depression and anemia in otherwise healthy adults","volume":"134","author":"H Vulser","year":"2016","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"pone.0323843.ref016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPH.0b013e3181d869d5","article-title":"Depression, anxiety, and stress comorbidities in sickle cell anemia patients with vaso-occlusive crisis","volume":"32","author":"N Mahdi","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"pone.0323843.ref017","first-page":"117","article-title":"Psychological outcomes associated with anemia-related fatigue in cancer patients","volume":"16","author":"JD Kallich","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"pone.0323843.ref018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139791","article-title":"Medically Attended Anxiety or Depression Is Increased Among Newly Diagnosed Patients with Cold Agglutinin Disease (CAD)","volume":"136","author":"P Patel","year":"2020","journal-title":"Blood"},{"key":"pone.0323843.ref019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-140335","article-title":"Inflammation and Fatigue in Patients with Cold Agglutinin Disease (CAD): Analysis from the Phase 3 Cardinal Study","volume":"136","author":"IC Weitz","year":"2020","journal-title":"Blood"},{"issue":"10","key":"pone.0323843.ref020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"S Berentsen","year":"2021","journal-title":"Blood"},{"issue":"14","key":"pone.0323843.ref021","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in Cold Agglutinin Disease","volume":"384","author":"A R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0323843.ref022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"A R\u00f6th","year":"2022","journal-title":"Blood"},{"issue":"19","key":"pone.0323843.ref023","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"W Barcellini","year":"2014","journal-title":"Blood"},{"issue":"6","key":"pone.0323843.ref024","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ejh.12199","article-title":"Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia","volume":"91","author":"W Barcellini","year":"2013","journal-title":"Eur J Haematol"},{"issue":"8","key":"pone.0323843.ref025","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"S Berentsen","year":"2004","journal-title":"Blood"},{"issue":"4","key":"pone.0323843.ref026","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies","volume":"14","author":"Q Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"pone.0323843.ref027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"C Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"pone.0323843.ref028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"S Berentsen","year":"2017","journal-title":"Blood"},{"issue":"17","key":"pone.0323843.ref029","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"S Berentsen","year":"2010","journal-title":"Blood"},{"issue":"19","key":"pone.0323843.ref030","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"A R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"pone.0323843.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"EI Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"pone.0323843.ref032","first-page":"1","article-title":"The auto-immune haemolytic anaemias: introduction.","volume-title":"The haemolytic anaemias","author":"J. Dacie","year":"1992"},{"key":"pone.0323843.ref033","author":"National Organization of Rare Diseases (NORD)","year":"2020"},{"key":"pone.0323843.ref034","author":"Rare Disease Advisor"},{"issue":"1","key":"pone.0323843.ref035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12288-020-01326-4","article-title":"Clinical Profile and Severity of Hemolysis in Adult Patients of Primary Autoimmune Hemolytic Anemia and Their Response to Steroid: A Prospective Cohort Study from Single Institution","volume":"37","author":"GK Ray","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"pone.0323843.ref036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-137545","article-title":"Autoimmune hemolytic anemia: A disease of the elderly and the very elderly with increased mortality and increased rates of hospitalization for thrombosis and infection","volume":"136","author":"J Maquet","year":"2020","journal-title":"Blood"},{"issue":"3","key":"pone.0323843.ref037","doi-asserted-by":"crossref","first-page":"102468","DOI":"10.1016\/j.autrev.2020.102468","article-title":"Estrogen, estrogen-like molecules and autoimmune diseases","volume":"19","author":"J Merrheim","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"pone.0323843.ref038","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/eva.13167","article-title":"Why women have more autoimmune diseases than men: An evolutionary perspective","volume":"14","author":"VL Kronzer","year":"2021","journal-title":"Evol Appl"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:48:28Z","timestamp":1750960108000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323843"}},"subtitle":[],"editor":[{"given":"Omid","family":"Beiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323843","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}